Endo Aims To Stabilize Generics Unit In 2021

Company Delivers Another Underwhelming Quarter

Endo will focus on restructuring initiatives and new launches in 2021 to stabilize its generics business, after the company reported a 20% drop in generics sales for the fourth quarter of 2020, with full-year sales down by more than a tenth.

competition
Endo expects to see additional competition on its “higher revenue products” in 2021 • Source: Shutterstock

“Once we are past 2021’s set of events, we are going to see a more stable generics portfolio,” assured Endo International president and CEO, Blaise Coleman, as he announced that the company would be focusing on restructuring initiatives to bolster profitability, accompanied by new launches, going forward.

After seeing its generics segment perform poorly back-to-back in the past few quarters, Endo reported a 20% drop in its...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business